ZymoGenetics begins Phase 1 trial of IL-21 with Rituxan

SarahTurner

LONDON (MarketWatch) -- ZymoGenetics Inc.
zgen
said that that a Phase 1 clinical trial is underway using Interleukin 21 (IL-21) in combination with the monoclonal antibody Rituxan. The open label dose-escalation trial is enrolling patients with advanced non-Hodgkin's lymphoma in a multi-site study conducted in the U.S. ZymoGenetics is developing IL-21 for the treatment of cancer and said the primary objective of the study is to evaluate the safety and tolerability of IL-21 when administered with Rituxan.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.